OptimizeRx’s (OPRX) Buy Rating Reiterated at Roth Mkm

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reissued by Roth Mkm in a research note issued on Thursday,Benzinga reports. They presently have a $16.00 price target on the stock, down from their prior price target of $20.00. Roth Mkm’s price target suggests a potential upside of 318.30% from the stock’s current price.

A number of other brokerages have also weighed in on OPRX. JMP Securities cut their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday. Royal Bank of Canada reduced their price objective on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. B. Riley assumed coverage on OptimizeRx in a report on Thursday, July 25th. They issued a “buy” rating and a $18.50 target price for the company. Stifel Nicolaus cut their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Barclays lowered their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx has a consensus rating of “Moderate Buy” and an average price target of $10.42.

OptimizeRx Stock Performance

OPRX opened at $3.83 on Thursday. The firm has a market cap of $70.07 million, a P/E ratio of -2.88 and a beta of 1.32. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The business’s fifty day moving average is $6.60 and its 200-day moving average is $8.99. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $16.65.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares during the last quarter. Connors Investor Services Inc. increased its holdings in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares in the last quarter. Summit Securities Group LLC acquired a new position in OptimizeRx in the second quarter valued at approximately $25,000. Rhumbline Advisers boosted its holdings in shares of OptimizeRx by 9.2% during the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after buying an additional 2,658 shares in the last quarter. Finally, Greenwood Capital Associates LLC increased its stake in shares of OptimizeRx by 8.0% in the 3rd quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after acquiring an additional 4,999 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.